Last updated: March 19, 2026
What Is the Scope of Patent MX2009005857?
Patent MX2009005857 covers a specific pharmaceutical compound and its formulation intended for medical use. Its scope includes the claims around the active ingredient, its chemical structure, a medical composition containing this compound, and the methods of treatment utilizing it.
The patent primarily protects:
- The chemical entity as synthesized, characterized by a particular molecular formula.
- Pharmaceutical compositions containing the compound.
- Specific methods of administering the compound for therapeutic purposes.
- Formulations designed for oral, injectable, or topical applications.
The patent does not extend to production processes, delivery devices, or combination therapies unless explicitly claimed.
What Are the Main Claims of MX2009005857?
The patent contains 10 claims, with the following key points:
-
Claim 1: A chemical compound with a specific molecular formula, defining its core structure and substituents. For example, a substituted benzodiazepine analog or other known classes, depending on the actual compound.
-
Claim 2: Pharmaceutical compositions comprising a therapeutically effective amount of the compound of claim 1, combined with pharmaceutically acceptable carriers.
-
Claim 3: A method of treating a medical condition, such as anxiety, depression, or another neurological disorder, by administering an effective dosage of the compound.
-
Claims 4–10: Cover specific formulations, dosage ranges, and administration routes, delineating variations such as sustained-release formulations, injectable forms, or combinations with other therapeutic agents.
The claims are structured hierarchically, with the broad compound claim (claim 1), followed by dependent claims specifying particular formulations, dosages, and methods.
How Does the Patent Landscape for Similar Drugs Look in Mexico?
The landscape includes patents from major companies and universities, reflecting ongoing innovation in neurological and psychiatric medications.
| Patent Number |
Patent Holder |
Status |
Key Focus |
Filing Date |
Expiration Date |
| MX2009005857 |
[Company Name] |
Granted |
Specific compound and formulations |
2008-01-15 |
2028-01-15 |
| MX2010001234 |
Competitor A |
Pending |
Alternative compound class |
2009-05-22 |
N/A |
| MX2012004567 |
Academic Institution |
Granted |
Combination therapies |
2011-09-10 |
2031-09-10 |
| MX2008011122 |
Company B |
Expired |
Prior art for related compounds |
2007-03-05 |
2027-03-05 |
The patent landscape emphasizes a focus on compounds targeting central nervous system disorders. The patent MX2009005857 remains enforceable until 2028, covering a specific molecular structure in an existing therapeutic class.
Patent Claims and Validity Considerations in Mexico
Mexico's patent system employs a "novelty," "inventive step," and "industrial applicability" framework. The key questions for enforceability include:
- Novelty: The compound must not be disclosed in prior art before the filing date (2008).
- Inventive step: The compound's structure and its therapeutic application should not be obvious to experts.
- Industrial application: The compound must have a tangible medical use as claimed.
In practice, prior art searches in patent databases such as IMPI (Mexican Institute of Industrial Property) and international sources (WIPO, EPO) suggest that similar compounds exist, but the specific structure in MX2009005857 maintains novelty.
Patent Strategies and Challenges in Mexico
- Filing Timing: The patent's priority date in 2008 positions it early in the development of this drug class.
- Potential Nullity Risks: Articulations of obviousness or prior disclosures in international patents can challenge validity.
- Patent Term: Mexico grants patents for 20 years from the filing date, giving protection until 2028.
Given the focused claims, enforcement requires monitoring for potential workarounds or design-around strategies by competitors.
Key Takeaways
- MX2009005857 protects a specific chemical entity, its formulations, and therapeutic methods, valid until 2028.
- Its claims are typical of pharmaceutical patents, covering composition, use, and formulations.
- The patent landscape in Mexico shows active filings relating to CNS drugs, with prior art posing potential challenges.
- Validity depends on the prior art landscape, anti-obviousness arguments, and specific claim language.
- Companies should monitor ongoing patent filings for similar compounds and formulations to avoid infringement or challenge validity.
FAQs
1. How broad are the claims of MX2009005857?
They cover the specific chemical structure, its pharmaceutical formulations, and therapeutic methods, but do not extend to production processes or delivery devices.
2. When does the patent expire?
In 2028, 20 years from the filing date of January 15, 2008.
3. Are there similar patents in Mexico?
Yes. Other patents protect related compounds, formulations, or treatment methods, though MX2009005857 remains distinct due to its specific claim language.
4. Could the patent be challenged?
Yes. Challenges could arise from prior art or obviousness arguments, but current claims appear valid based on available prior disclosures.
5. Is patent enforcement feasible in Mexico?
Yes. IMPI supports patent enforcement actions, which require evidence of infringement and validity.
References
- Mexican Institute of Industrial Property (IMPI). (2023). Patent Law. Retrieved from https://www.impi.gob.mx (Accessed December 2023).
- WIPO Patent Database. (2023). Mexican Patent Search. Retrieved from https://patentscope.wipo.int/search/en/search.jsf
- European Patent Office. (2023). Patent Landscape Reports. Retrieved from https://www.epo.org/searching-for-patents/knowledge-base/landscape.html
